Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDI-CaP
2025-521170-33-00Phase 2Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tissue-plasminogen activator in prostate cancer (PCa), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Erectile function recovery at 6 months after hormonal therapy cessation. Planned start Jul 2025; status: authorised.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2025-521170-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521170-33-00.